Skip to content

Apogee Therapeutics, Inc. APGE Other Income (Expense)

Other Income (Expense) at other companies

Eli Lilly logo
Eli LillyLLY
-$65M+72.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$188.3M-39.9%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$5.79M+47.0%
Arrowhead Research logo
Arrowhead ResearchARWR
$3.7M+132%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX

Other financials

Income statement

See full
Operating income-$82.8M-31.2%
Net income-$74.1M-33.9%
EPS (diluted)-$1.06-11.6%

Balance sheet

See full
Cash & equivalents$451.8M+323%
Total debt$8.0M-31.9%
Total assets$1.3B+81.1%

Cash flow

See full
Operating cash flow-$55.6M-14.6%
CapEx$62.0K
Free cash flow-$62.8M+7.3%

Valuation

See full
Market cap$6.81B+189%
Enterprise value$6.37B+181%

Returns & leverage

See full
Current ratio32.6×+16.8×

Where this comes from

Reported directly by Apogee Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apogee Therapeutics, Inc.'s other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Apogee Therapeutics, Inc.'s other income (expense)?
Apogee Therapeutics, Inc. (APGE) reported other income (expense) of $8.74M in Q1 2026.
How has Apogee Therapeutics, Inc.'s other income (expense) changed year-over-year?
Apogee Therapeutics, Inc.'s other income (expense) increased by 11.5% year-over-year, from $7.84M to $8.74M.
What is the long-term trend for Apogee Therapeutics, Inc.'s other income (expense)?
Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s other income (expense) has grown at a 82.5% compound annual growth rate (CAGR), from $9.02M to $30.03M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.